Samuel Costello
Dr Sam Costello MD PhD is a leader in microbiome drug development. He co-founded BiomeBank in 2019 and led the team to achieve the world’s first approval for a microbiome therapy. BIOMICTRA is now supplied to over 80 Australian hospital networks. Sam helped develop BiomeBank’s Consortiome platform for scalable cultured microbiome therapy production. He trained in Gastroenterology at The Queen Elizabeth Hospital (Australia) and St Mark’s Hospital (UK), and completed a PhD at the University of Adelaide focused on FMT for ulcerative colitis. He has raised over $20M AUD, secured multiple patents, and contributed to international microbiome therapy guidelines.
Abstracts this author is presenting:
